View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/CMS RIN: 0938-AT87 Publication ID: Spring 2019 
Title: Regulation to Require Drug Pricing Transparency (CMS-4187-F) 
Abstract:

This final rule responds to comments received on the proposal revising the Federal Health Insurance Programs for the Aged and Disabled by amending the Medicare Parts A, B, C and D programs, as well as the Medicaid program, to require drug pricing transparency.

 
Agency: Department of Health and Human Services(HHS)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Yes  Unfunded Mandates: No 
EO 13771 Designation: Regulatory 
CFR Citation: 42 CFR 403   
Legal Authority: 42 U.S.C. 1302    42 U.S.C. 1395hh   
Legal Deadline:
Action Source Description Date
Final  Statutory  MMA sec. 902 requires Medicare final rules publish within 3 years of a proposed or interim final rule or by an earlier target announced by the Secretary.  12/31/2019 
Timetable:
Action Date FR Cite
NPRM  10/18/2018  83 FR 52784   
NPRM Comment Period End  12/17/2018 
Final Action  12/00/2019 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Cheri Rice
Deputy Director, Center for Medicare, Parts C & D
Department of Health and Human Services
Centers for Medicare & Medicaid Services
Center for Medicare, MS: C1-13-07, 7500 Security Boulevard,
Baltimore, MD 21244
Phone:410 786-3000